https://pharmaphorum.com/ en Fri, 20 Dec 2024 13:31:33 +0000 Thu, 19 Dec 2024 17:48:52 +0000 https://pharmaphorum.com/news/novartis-sheds-morphosys-staff-sites-after-pelabresib-delay Novartis has confirmed it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, by the end of next year. Phil.Taylor https://pharmaphorum.com/news/novartis-sheds-morphosys-staff-sites-after-pelabresib-delay 2024-12-19T17:48:52+0000 Feed - News and features https://pharmaphorum.com/news/vertex-weakens-after-neuropathic-pain-trial-reads-out A trial of Vertex's suzetrigine in neuropathic back pain met its primary objective, but shares in the company fell as investors reacted to the data. Phil.Taylor https://pharmaphorum.com/news/vertex-weakens-after-neuropathic-pain-trial-reads-out 2024-12-19T16:55:22+0000 Feed - News and features https://pharmaphorum.com/news/neuralink-rival-precision-raises-102m-and-other-financings Neuralink rival Precision Neurosciences raises $102m for its brain-computer interface tech, plus financings for Redesign, DeepLife, TG0 and Tuva. Phil.Taylor https://pharmaphorum.com/news/neuralink-rival-precision-raises-102m-and-other-financings 2024-12-19T15:48:58+0000 Feed - News and features https://pharmaphorum.com/news/roches-parkinsons-hope-fails-second-clinical-trial Roche and Prothena's alpha-synuclein-targeting prasinezumab for Parkinson's fails again, leaving them sifting through the data for efficacy signals. Phil.Taylor https://pharmaphorum.com/news/roches-parkinsons-hope-fails-second-clinical-trial 2024-12-19T14:11:15+0000 Feed - News and features https://pharmaphorum.com/news/novo-completes-165bn-takeover-catalent Novo Holdings' $16.5bn takeover of US CDMO Catalent has been completed, after months of debate over potential antitrust issues. Phil.Taylor https://pharmaphorum.com/news/novo-completes-165bn-takeover-catalent 2024-12-19T13:18:54+0000 Feed - News and features